⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme

Official Title: Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme

Study ID: NCT00014300

Interventions

glufosfamide

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of glufosfamide in treating patients who have recurrent glioblastoma multiforme.

Detailed Description: OBJECTIVES: I. Determine the activity of glufosfamide, in terms of objective response rate and/or progression-free survival at 6 months, in patients with recurrent glioblastoma multiforme. II. Determine the duration of objective response in patients treated with this regimen. III. Determine the toxic effects and pharmacokinetic profile of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive glufosfamide IV over 60 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive treatment for a minimum of 6 months or until progression. Patients with an objective complete response receive a maximum of 2 additional courses of treatment after confirmation of response. Patients are followed every 6 weeks until progression. PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Kaiser Franz Josef Hospital, Vienna (Wien), , Austria

Centre Jean Perrin, Clermont-Ferrand, , France

Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, , France

Centre Leon Berard, Lyon, , France

CRLCC Nantes - Atlantique, Nantes-Saint Herblain, , France

Centre Antoine Lacassagne, Nice, , France

CHU Pitie-Salpetriere, Paris, , France

Centre Eugene Marquis, Rennes, , France

Institut Gustave Roussy, Villejuif, , France

University of Ioannina, Ioannina, , Greece

Schneider Children's Medical Center of Israel, Petah-Tikva, , Israel

Azienda Ospedaliera di Padova, Padova (Padua), , Italy

Istituti Fisioterapici Ospitalieri - Roma, Rome, , Italy

Rotterdam Cancer Institute, Rotterdam, , Netherlands

Academisch Ziekenhuis Utrecht, Utrecht, , Netherlands

Instituto Portugues de Oncologia de Francisco Gentil, Lisbon, , Portugal

Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland

Kantonsspital - St. Gallen, St. Gallen, , Switzerland

Contact Details

Name: Martin J. van Den Bent, MD

Affiliation: Daniel Den Hoed Cancer Center at Erasmus Medical Center

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: